🔎 Trials Near Me

Akèy › Skleroderm Difize › Iowa

Etid klinik pou Skleroderm Difize nan Iowa

3 etid pou Skleroderm Difize ap chèche patisipan nan sit nan Iowa.

Vil nan Iowa

Tèks ofisyèl etid la (Anglè)

A Study to Investigate the Safety and Preliminary Efficacy of ALLO-329, an Allogeneic CAR T-cell Therapy, in Adults With Autoimmune Disease

  • University of Iowa, Iowa City
Ap rekriteFaz 1
Laj 18 a 74 · Tout sèks · Mizajou Sep 10, 2026 · NCT07085104

A Safety and Efficacy Study Evaluating CTX112 in Adult Subjects With Refractory Autoimmune Disease

  • University of Iowa, Iowa City
Ap rekriteFaz 1
Laj 18 a 70 · Tout sèks · Mizajou Aug 28, 2026 · NCT06925542

AlloNK®, an Allogeneic Non-genetically Modified, Cord Blood-derived NK Cell Therapy, in Combination With Rituximab, Studied in Relapsing Forms of B-cell Dependent Rheumatologic Diseases.

  • Artiva Investigational Site Iowa, Iowa City
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Jul 31, 2026 · NCT06991114

Sous ClinicalTrials.gov, done yo ranmase Oct 1, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.